GLP-1 stimulation in the microbiome Human intestinal cells show Akkermansias effect on GLP-1 production Akkermansia secretes p9 protein which stimulates GLP-1 production Clostridium butyricum increases GLP-1* Dose-dependent increase of GLP-1 by Clostridium butyricum in a cell-based assay *Based on internal Pendulum R&D data Breakthrough clinical research Were continually pushing the boundaries in scientific research, and were excited to conduct a human clinical trial on GLP-1 and the gut microbiome
In agreement with experimental studies, GLP-1 analogues, particularly liraglutide, sustain the maintenance of -cell function in obese individuals with early T2D, and these effects are presumably independent of weight loss (42, 43)
Two popular options for the treatment of obesity are bariatric surgery (e.g
Over the course of treatment, the study participants lost weight, their cardiometabolic parameters improved and their free testosterone levels which tend to be elevated in women with PCOS decreased
GLP-1RAs can improve cell function in patients with early T2DM via coordinated regulation of the fate of and cells
Real-world outcomes: According to a 72-week phase 3b trial, adults with obesity (but without diabetes) treated with tirzepatide were significantly more likely to lose at least 10% or 15% of their body weight than those treated with semaglutide
